Sugi Predict

Sugi Predict / Compounds / SCHEMBL240589

SCHEMBL240589

SCHEMBL240589

COC(=O)N[C@H](C(=O)O)C1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 3/20 0.42
▸ MMP1 P03956 1/20 0.42
▸ MMP3 P08254 1/20 0.42
▸ MMP7 P09237 1/20 0.42
▸ MMP13 P45452 1/20 0.42
▸ CA12 O43570 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PYGL P06737 7/20 0.38
▸ AAK1 Q2M2I8 1/20 0.38
▸ CYP2C9 P11712 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1804269 1.00 MMP2 (0.42) MMP2MMP1MMP3MMP7MMP13
SCHEMBL241407 0.98 MMP2 (0.44) MMP2MMP1MMP3MMP7MMP13
SCHEMBL6435900 0.98 MMP2 (0.44) MMP2MMP1MMP3MMP7MMP13
SCHEMBL204610 0.98 MMP2 (0.44) MMP2MMP1MMP3MMP7MMP13
SCHEMBL239875 0.96 MMP2 (0.39) MMP2MMP1MMP3MMP7MMP13
SCHEMBL27923509 0.96 MMP2 (0.39) MMP2MMP1MMP3MMP7MMP13
SCHEMBL206034 0.92 MMP2 (0.37) MMP2MMP1MMP3MMP7MMP13
SCHEMBL193724 0.92 MMP2 (0.37) MMP2MMP1MMP3MMP7MMP13
SCHEMBL12654802 0.85 MMP2 (0.40) MMP2MMP1MMP3MMP7MMP13
SCHEMBL5988909 0.85 MMP2 (0.40) MMP2MMP1MMP3MMP7MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP claimed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US claimed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 — — US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 — — US disclosed
CN-106986861-A Antiviral compound 艾伯维巴哈马有限公司 2017-07-28 — — CN disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 — — US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 — — US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 — — EP disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 — — US disclosed
EP-2393359-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES Enanta Pharmaceuticals, Inc. (US) 2011-12-14 — — EP disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 — — US disclosed
WO-2011054834-A1 BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES TIBOTEC PHARMACEUTICALS (IE) 2011-05-12 — — WO disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-10-21 — — US disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 — — WO disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 — — US disclosed
WO-2010091413-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267634-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 MMP2 4196/4885MMP1 4423/4885MMP3 4560/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.